Prolonged ovarian sex steroid treatment of male... : Pain (original) (raw)

Prolonged ovarian sex steroid treatment of male rats produces antinociception: identification of sex-based divergent analgesic mechanisms

Nai-Jiang Liu
Alan R. Gintzler

Pain

85(2):p 273-281, March 1, 2000.

| DOI: 10.1016/S0304-3959(99)00278-X

Abstract

Simulation of the pregnancy blood concentration profile of 17β-estradiol (E2) and progesterone (P) in nonpregnant ovariectomized rats has been shown to result in a significant elevation of nociceptive response thresholds. The present report demonstrates that spinal opioid antinociceptive responsiveness to these ovarian steroids is not sex-specific. Treatment of orchidectomized sexually mature males with an analogous regimen of E2 and P also elicits an antinociception, the robustness and temporal profile of which is comparable with that previously observed in females. Neither E2 nor P, alone, is sufficient to produce antinociception in male rats, as was previously demonstrated in females. Neurobiological substrates and antinociceptive mechanisms underlying ovarian sex steroid antinociception do, however, exhibit sex specificity. In males, the analgesia resulting from ovarian steroid treatment derives from the independent contributions of spinal κ and μ, not δ, opioid receptor pathways that are additive, not synergistic. Spinal α2-noradrenergic receptor activity and its attendant analgesic synergy with spinal opioid systems do not contribute to ovarian sex steroid analgesia in males. This is in contrast to the previous demonstrations that ovarian sex steroid-induced antinociception in females results from antinociceptive synergy between activated spinal κ/δ opioid as well as α2-noradrenergic receptor systems. The current data reveal that ovarian steroid-activated multiplicative spinal antinociceptive pathways that had been demonstrated in female rats are not manifest in their male counterparts.